The table below is a review of notable updates that occurred in March 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

The company also announced the appointment of its current Executive Chair, Alvin Shih, MD to the Chief Executive Officer role, plus the appointment of Rebecca Luse, Managing Director at Deep Track ...

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

In this video, Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA, discusses notable updates across several areas of cardiology ...

Corvista Health’s point-of-care device, used to predict pulmonary hypertension (PH), also appears to work well at identifying ...

The identification and management of comorbidities are central to the care of patients with atrial fibrillation (AF). The ...

Inflammatory arthritis encompasses a group of autoimmune diseases, including rheumatoid arthritis (RA), psoriatic arthritis ...

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

Human Heat Tolerance Lower Than Previously Believed: Study FindsA study from the University of Ottawa’s Human and Environmental Physiology Research ...

Cardiac illnesses are among the trickier ones to manage in the limited time provided for many primary care visits, with ...